Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Change in Account Payables (2016 - 2025)

iBio (IBIO) has disclosed Change in Account Payables for 16 consecutive years, with -$29000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 87.97% to -$29000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 263.8% increase, with the full-year FY2025 number at $1.8 million, up 222.8% from a year prior.
  • Change in Account Payables was -$29000.0 for Q4 2025 at iBio, down from $495000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.0 million in Q4 2022 to a low of -$1.7 million in Q1 2023.
  • A 5-year average of $48850.0 and a median of $70500.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 758.33% in 2021; the steepest drop was 828.44% in 2021.
  • iBio's Change in Account Payables stood at $793000.0 in 2021, then increased by 27.62% to $1.0 million in 2022, then crashed by 105.04% to -$51000.0 in 2023, then plummeted by 372.55% to -$241000.0 in 2024, then surged by 87.97% to -$29000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Change in Account Payables are -$29000.0 (Q4 2025), $495000.0 (Q3 2025), and $712000.0 (Q2 2025).